Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis.
Anticoagulation
Cirrhosis
Mortality
Portal vein thrombosis
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
16
03
2022
revised:
07
05
2022
accepted:
23
05
2022
pubmed:
7
6
2022
medline:
20
7
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Splanchnic vein thrombosis (SVT) occurs in a heterogenous group of patients secondary to a variety of risk factors including liver disease. Minimal data regarding natural history and outcomes of SVT exists to inform management decisions. As such, there is equipoise regarding the utility of anticoagulation in cirrhotic patients with SVT. We sought to identify clinical factors predictive of new or progressive thrombosis in a cohort of patients with untreated SVT. We conducted a retrospective cohort study of cirrhotic patients over 18 years of age diagnosed with SVT at the Oregon Health & Science University from 2015 to 2020, excluding those initially treated with anticoagulation. The primary study endpoint was a composite of the following: imaging-confirmed progression of SVT, development of cavernous transformation, intestinal ischemia, portal cholangiopathy or new venous or arterial thrombosis. 261 patients were included in the analysis (median age 61 years, 68% male, 32% female). Forty percent of all patients experienced the primary composite endpoint. Multivariable logistic regression found that only the presence of pancreatitis or abdominal infection at diagnosis was associated with an increased likelihood of experiencing thrombus progression in patients with untreated SVT (OR 3.61, P = 0.02). There was a statistically significant overall survival difference between patients that did and did not experience the primary composite endpoint after controlling for confounding variables. (p = 0.0068). Overall, only the presence of pancreatitis or intrabdominal infection were found to be significantly associated with thrombotic progression, with varices identified as marginally non-significant risk factor. Notably, thrombotic progression was associated with a significant reduction in overall survival.
Identifiants
pubmed: 35660708
pii: S0049-3848(22)00278-X
doi: 10.1016/j.thromres.2022.05.012
pmc: PMC9464500
mid: NIHMS1834383
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL151367
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
Pancreatology. 2022 Mar;22(2):235-243
pubmed: 35012902
Front Med (Lausanne). 2021 Jun 28;8:685944
pubmed: 34262917
J Thromb Haemost. 2011 Sep;9(9):1713-23
pubmed: 21729237
Vasc Health Risk Manag. 2019 Oct 22;15:449-461
pubmed: 31695400
J Gastroenterol. 2021 Jul;56(7):593-619
pubmed: 34231046
World J Gastroenterol. 2019 Aug 21;25(31):4437-4451
pubmed: 31496623
Thromb Res. 2019 Feb;174:137-140
pubmed: 30597344
Intern Emerg Med. 2008 Sep;3(3):213-8
pubmed: 18274708
Blood. 2021 Mar 4;137(9):1233-1240
pubmed: 32911539
Am J Gastroenterol. 2020 Jan;115(1):18-40
pubmed: 31895720
Am J Gastroenterol. 2009 Jan;104(1):96-101
pubmed: 19098856
Eur J Intern Med. 2015 Jan;26(1):23-9
pubmed: 25566699
Clin Transl Gastroenterol. 2018 Aug 15;9(8):176
pubmed: 30108204
Ann Gastroenterol. 2021;34(1):104-110
pubmed: 33414629
Adv Ther. 2021 Jan;38(1):495-520
pubmed: 33155180
Eur J Haematol. 2021 Oct;107(4):383-392
pubmed: 34258797
J Thromb Haemost. 2015 Feb;13(2):206-13
pubmed: 25471737
Dig Dis Sci. 2019 Sep;64(9):2671-2683
pubmed: 30852769
BMC Med. 2018 Jun 5;16(1):83
pubmed: 29871683
Medicine (Baltimore). 2021 Apr 23;100(16):e25439
pubmed: 33879676
Liver Int. 2012 Jul;32(6):919-27
pubmed: 22435854
Am J Gastroenterol. 2013 Apr;108(4):568-74
pubmed: 23381015
Am J Gastroenterol. 2019 Feb;114(2):258-266
pubmed: 30538290
Radiology. 2012 Oct;265(1):124-32
pubmed: 22891357
Hepatology. 2015 Feb;61(2):660-7
pubmed: 25284616
Saudi J Gastroenterol. 2014 Sep-Oct;20(5):288-92
pubmed: 25253363
Gastroenterol Res Pract. 2015;2015:245460
pubmed: 26451142
J Hepatol. 2009 Oct;51(4):682-9
pubmed: 19464747
J Hepatol. 2016 Jan;64(1):179-202
pubmed: 26516032
BMJ. 2018 Jul 18;362:k2817
pubmed: 30021785
Liver Int. 2018 Jan;38(1):94-101
pubmed: 28632958
Hematology Am Soc Hematol Educ Program. 2015;2015:243-9
pubmed: 26637729
Ann Gastroenterol. 2018 May-Jun;31(3):315-329
pubmed: 29720857
BMC Gastroenterol. 2007 Aug 15;7:34
pubmed: 17697371
J Hepatol. 2021 Dec;75(6):1367-1376
pubmed: 34333101
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e108-e113
pubmed: 33208682
J Hepatol. 2004 May;40(5):736-41
pubmed: 15094219
N Engl J Med. 2011 Jul 14;365(2):147-56
pubmed: 21751907
Clin Gastroenterol Hepatol. 2015 Mar;13(3):585-93
pubmed: 25459555
HPB (Oxford). 2011 Dec;13(12):860-4
pubmed: 22081920
Eur J Gastroenterol Hepatol. 2016 Jan;28(1):82-9
pubmed: 26513611
Hepatology. 2021 Jan;73(1):366-413
pubmed: 33219529
Gastroenterology Res. 2020 Feb;13(1):25-31
pubmed: 32095170
Gastroenterology. 2017 Aug;153(2):480-487.e1
pubmed: 28479379
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908